Insmed Incorporated Stock price

Equities

INSM

US4576693075

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-28 pm EDT 5-day change 1st Jan Change
27.13 USD -0.70% Intraday chart for Insmed Incorporated +3.00% -12.46%
Sales 2024 * 357M Sales 2025 * 503M Capitalization 4.03B
Net income 2024 * -722M Net income 2025 * -672M EV / Sales 2024 * 12.8 x
Net Debt 2024 * 558M Net Debt 2025 * 616M EV / Sales 2025 * 9.23 x
P/E ratio 2024 *
-5.92 x
P/E ratio 2025 *
-7 x
Employees 912
Yield 2024 *
-
Yield 2025 *
-
Free-Float 98.78%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.70%
1 week+3.00%
Current month-2.13%
1 month-3.21%
3 months-14.52%
6 months+5.32%
Current year-12.46%
More quotes
1 week
26.19
Extreme 26.19
27.55
1 month
25.52
Extreme 25.52
28.65
Current year
25.06
Extreme 25.06
31.14
1 year
16.26
Extreme 16.255
32.00
3 years
16.04
Extreme 16.04
36.97
5 years
12.09
Extreme 12.09
45.44
10 years
9.02
Extreme 9.02
45.44
More quotes
Managers TitleAgeSince
Chief Executive Officer 55 12-09-09
Director of Finance/CFO 43 20-01-30
Chief Tech/Sci/R&D Officer 60 19-12-18
Members of the board TitleAgeSince
Director/Board Member 60 20-03-31
Director/Board Member 65 12-08-01
Director/Board Member 73 01-04-30
More insiders
Date Price Change Volume
24-03-28 27.13 -0.70% 1,129,688
24-03-27 27.32 +1.11% 1,257,538
24-03-26 27.02 +0.07% 1,182,340
24-03-25 27 +2.16% 958,544
24-03-22 26.43 +0.34% 967,867

Delayed Quote Nasdaq, March 28, 2024 at 04:00 pm EDT

More quotes
Insmed Incorporated is a global biopharmaceutical company. The Company's first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib and TPIP, as well as other early-stage research programs. Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), which is developing for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases, including chronic rhinosinusitis without nasal polyps (CRSsNP). TPIP is an inhaled formulation of the treprostinil prodrug treprostinil palmitil, which offers a differentiated product profile for pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
27.13 USD
Average target price
43.67 USD
Spread / Average Target
+60.95%
Consensus
  1. Stock
  2. Equities
  3. Stock Insmed Incorporated - Nasdaq